ArticleFrontiers in immunology2025
Effective dose to immune cells combined with platelet-to-lymphocyte ratio predicts lymphopenia and prognosis in unresectable locally advanced non-small cell lung cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systemic inflammatory indices as accessible biomarkers for intracranial outcome and prognosis in driver gene-negative NSCLC with brain metastases treated with first-line chemoimmunotherapy.Discover oncology · 2026Article
- Vertebral body dosimetry associated with hematologic toxicities and survival in esophageal squamous-cell carcinoma treated with chemoradiotherapy plus immunotherapy.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the management of unresectable locally advanced non-small cell lung cancer (LA-NSCLC), the lack of reliable predictive biomarkers for grade ≥ 3 radiation-induced lymphopenia (RIL3+) and prognosis remains a major challenge. This study aims to investigate whether effective dose to immune cells (EDIC) combined with pre-radiotherapy (RT) peripheral blood inflammatory indicators (PBIIs), especially platelet-to-lymphocyte ratio (PLR), could better predict RIL3+ and prognosis in patients with unresectable LA-NSCLC in the immunotherapy era. Methods: We enrolled 139 patients with unresectable LA-NSCLC who received chemoradiation and consolidation immunotherapy. Logistic regression was used to identify the predictors of RIL3+. Spearman correlation analyses were used to estimate the correlations between each indicator and absolute lymphocyte count (ALC) nadir. Receiver operating characteristic (ROC) curves were used to determine the predictive performance and optimal cut-off of each indicator. Patients were then divided into low- and high-risk groups based on the above cut-offs. Cox proportional hazards regression was used to determine prognostic factors for progression-free survival (PFS) and overall survival (OS). Survival outcomes were assessed using Kaplan-Meier methods. Results: Logistic regression showed that both EDIC ( Conclusions: In the immunotherapy era, the combination of EDIC and pre-RT PLR is a predictive biomarker of RIL3+ and prognosis in patients with unresectable LA-NSCLC. Reducing EDIC and considering pre-RT PLR may potentially avoid RIL3+ and improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.